Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
ZyCoV-D
Novartis'_stake_in_consumer_health |
| gptkbp:CEO |
gptkb:Emma_Walmsley
|
| gptkbp:clinicalTrials |
over 30 countries
data sharing agreements collaborations with universities over 100 ongoing regulatory compliance efforts Phase III trials for new drugs patient recruitment initiatives |
| gptkbp:community_engagement |
disaster relief efforts
health education programs volunteer programs partnerships with NGOs support for local health initiatives |
| gptkbp:dividendYield |
4.5% (2022)
|
| gptkbp:employees |
99,000 (2022)
|
| gptkbp:focus |
pharmaceuticals
vaccines consumer healthcare |
| gptkbp:founded |
2000
|
| gptkbp:global_presence |
manufacturing facilities worldwide
operations in over 100 countries collaborations with local companies sales in emerging markets research_centers_in_the_UK,_US,_and_Belgium |
| gptkbp:headquarters |
Brentford,_England
|
| https://www.w3.org/2000/01/rdf-schema#label |
GSK
|
| gptkbp:impact |
developed_in_partnership_with_Sanofi
|
| gptkbp:market |
$90 billion (2022)
|
| gptkbp:notable_player |
gptkb:Shingrix
gptkb:Bexsero Menveo FluLaval |
| gptkbp:partnerships |
gptkb:Vir_Biotechnology
gptkb:AstraZeneca gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Immunocore gptkb:Sangamo_Therapeutics gptkb:MedImmune |
| gptkbp:research_areas |
HIV
oncology infectious diseases immunology respiratory diseases |
| gptkbp:research_focus |
gene therapy
mRNA technology biologics small molecules cell therapy |
| gptkbp:researchAndDevelopment |
$6 billion (2022)
|
| gptkbp:revenue |
$43 billion (2022)
|
| gptkbp:stockExchange |
gptkb:GSK
gptkb:London_Stock_Exchange |
| gptkbp:subsidiary |
ViiV Healthcare
Haleon |
| gptkbp:sustainability_initiatives |
carbon neutrality by 2030
improving access to medicines zero waste to landfill by 2025 sustainable sourcing of raw materials |